Antioxidant Vitamins and Their Use in Psychiatry

Abstract

Oxidative stress can be defined as imbalance between prooxidant molecules produced during body metabolism and members of antioxidant system for favor of former. Oxidative stress, which is included in the pathogenesis of cancer, aging, cardiovascular and neurodegenerative disorders, is also considered for pathogenetic mechanisms underlying psychiatric disorders including schizophrenia, mood disorders, attention deficit hyperactivity disorder. Due to important role of antioxidant vitamins in antioxidant defense mechanisms, vitamin supplementation therapies are considered in addition to conventional treatment choices for psychiatric disorders. This paper will attempt to review the biochemical, molecular and genetic data on biological processes related to vitamins A, C and E. Besides, the circumstances under which the antioxidant vitamin supplementation could be used in psychiatry and the factors that should be taken into consideration during these therapies will be discussed.

Keywords

• vitamin A, vitamin E, ascorbic acid

Antioksidan Vitaminler ve Psikiyatride Kullanımı

Öz

Oksidatif stres, vücut metabolizması sırasında üretilen serbest radikaller ve bunların vücuttan temizlenmesi ile ilgili antioksidan sistem elemanları arasındaki dengenin serbest radikaller lehine bozulması durumudur. Kanser, kardiyovasküler hastalıklar ve nörodejeneratif hastalıkların etiyolojisinde etkili olduğu düşünülen oksidatif stres, aynı zamanda şizofreni, duygudurum bozuklukları, otizm, dikkat eksikliği hiperaktivite bozukluğu gibi bazı ruhsal bozuklukların patogenezinde de sorumlu mekanizmalardan birisi olarak görülmektedir. Bu bağlamda ruhsal bozuklukların bilinen mevcut tedavileri dışında antioksidan vitamin ekleme tedavileri gündeme gelmiştir. Bu süreçte yer alan A, C ve E vitaminleri antioksidan savunmayı desteklemek dışında bazı ruhsal bozukluklarda görülebilen beslenme sorunlarına ikincil eksikliklerde de kullanılabilmektedir. Bu yazıda A, C ve E vitaminlerinin vücuttaki süreçlerine ilişkin biyokimyasal, moleküler ve genetik veriler gözden geçirilecek daha sonra antioksidan vitaminlerin ekleme tedavilerinin psikiyatride hangi koşullarda gündeme gelebileceği ve uygulanması halinde dikkat edilmesi gereken faktörler tartışılacaktır.

Anahtar Kelimeler

• Vitamin A, vitamin E, askorbik asid

References

1. Jaruga P, Zastawny TH, Skokowski J, Dizdaroglu M, Olinski R. Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Lett 1994; 341:59-64.
2. Khatri JJ, Johnson C, Magid R, Lessner SM, Laude KM, Dikalov SI et al. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 2004; 109:520-525.
3. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann Neurol 1994; 36:747-751.
4. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11:851-876.
5. Chauhan A, Chauhan V. Oxidative stress in autism. Pathophysiology 2006; 13:171- 181.
6. Bulut M, Selek S, Gergerlioglu SH, Savas HA, Yilmaz HR, Yuce M et al. Malondialdehyde levels in adult attention-deficit hyperactivity disorder. J Psychiatry Neurosci 2007; 32:435-438.
7. Shulman RG, Rothman DL, Behar KL, Hyder F. Energetic basis of brain activity:implications for neuroimaging. Trends Neurosci 2004; 27:489-495.
8. Betteridge DJ. What is oxidative stress? Metabolism 2000; 49 (suppl 1):3-8.

9. Kannan K, Jain SK. Oxidative stress and apoptosis. Pathophysiology 2000; 7:153- 163.
10. Mates JM. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 2000; 153:83-104.
11. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of ω-3 fatty acids and antioxidants (vitamin E and C) improves the outcome of schizophrenia. Schizophr Res 2003; 62:195-204.
12. McAbee GN, Prieto DM, Kirby J, Santilli AM, Setty R. Permanent visual loss due to dietary vitamin A deficiency in an autistic adolescent. J Child Neurol 2009; 24:1288- 1289.
13. Cole JA, Warthan MM, Hirano SA, Gowen CW Jr, Williams JV. Scurvy in a 10- year-old boy. Pediatr Dermatol 2011; 28:444-446.
14. Heiser P, Sommer O, Schmidt AJ. Effects of antipsychotics and vitamin C on the formation of reactive oxygen species. J Psychopharmacol 2010; 24:1499-1504.
15. Bremner JD, McCaffery P. The neurobiology of retinoic acid in affective disorders. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:315–331.
16. Harrison EH. Mechanisms involved in the intestinal absorption of dietary vitamin A and provitamin A carotenoids. Biochim Biophys Acta 2012; 1821:70-77.
17. During A, Harrison EH. Mechanisms of provitamin A (carotenoid) and vitamin A (retinol) transport into and out of intestinal Caco-2 cells. J Lipid Res 2007;48:2283- 2294.
18. Lietz G, Lange J, Rimbach G. Molecular and dietary regulation of β,β-carotene 15,15′-monooxygenase 1 (BCMO1). Arch Biochem Biophys 2010; 502:8-16.
19. Crow JA, Ong DE. Cell-specific immunohistochemical localization of a cellular retinol-binding protein (type two) in the small intestine of rat. Proc Natl Acad Sci USA 1985; 82:4707-4711.
20. Blomhoff R, Blomhoff HK. Overview of retinoid metabolism and function. J Neurobiol 2006; 66:606-630.
21. Reboul E, Borel P. Proteins involved in uptake, intracellular transport and basolateral secretion of fat-soluble vitamins and carotenoids by mammalian enterocytes. Prog Lipid Res 2011; 50:388-402.
22. Kawaguchi R, Yu J, Honda J, Hu J, Whitelegge J, Ping P et al. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science 2007; 315:820-825.
23. Kawaguchi R, Yu J, Ter-Stepanian M, Zhong M, Cheng G, Yuan Q et al. Receptor mediated cellular uptake mechanism that couples to intracellular storage. ACS Chem Biol 2011; 6:1041-1051.
24. Bouillet P, Sapin V, Chazaud C, Messaddeq N, Décimo D, Dollé P et al. Developmental expression pattern of Stra6, a retinoic acid-responsive gene encoding a new type of membrane protein. Mech Dev 1997; 63:173-186.
25. Olson CR, Mello CV. Significance of vitamin A to brain function, behavior and learning. Mol Nutr Food Res 2010; 54:489-495.
26. Gelain DP, Cammarota M, Zanotto-Filho A, de Oliveira RB, Dal-Pizzol F, Izquierdo I et al. Retinol induces the ERK1/2-dependent phosphorylation of CREB through a pathway involving the generation of reactive oxygen species in cultured Sertoli cells. Cell Signal 2006; 18:1685-1694.
27. Samad TA, Krezel W, Chambon P, Borrelli E. Regulation of dopaminergic pathways by retinoids:Activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. Proc Natl Acad Sci USA 1997; 94:14349-14354.
28. O’Reilly KC, Trent S, Bailey SJ, Lane MA. 13-cis-retinoic acid alters intracellular serotonin, increases 5-HT1A receptor, and serotonin reuptake transporter levels in vitro. Exp Biol Med (Maywood) 2007; 232:1195-1203.
29. Matsuoka I, Kumagai M, Kurihara K. Differential and coordinated regulation of expression of norepinephrine transporter in catecholaminergic cells in culture. Brain Res 1997; 776:181-188.
30. McCaffery P, Zhang J, Crandall JE. Retinoic acid signaling and function in the adult hippocampus. J Neurobiol 2006; 66:780-791.
31. Wang HF, Liu FC. Regulation of multiple dopamine signal transduction molecules by retinoids in the developing striatum. Neuroscience 2005; 134:97-105.
32. Bremner JD, Fani N, Ashraf A, Votaw JR, Brummer ME, Cummins T et al. Functional brain imaging alterations in acne patients treated with isotretinoin. Am J Psychiatry 2005; 162:983-991.
33. Lane MA, Bailey SJ. Role of retinoid signalling in the adult brain. Prog Neurobiol 2005; 75:275-293.
34. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001; 45:515-519.
35. O’Reilly K, Bailey S, Lane MA. Retinoid-mediated regulation of mood:possible cellular mechanisms. Exp Biol Med (Maywood) 2008; 233:251-258.
36. Cocco S, Diaz G, Stancampiano R, Diana A, Carta M, Curreli R et al. Vitamin A deficiency produces spatial learning and memory impairment in rats. Neuroscience 2002; 115:475-482.
37. Tafti M, Ghyselinck NB. Functional implication of the vitamin A signaling pathway in the brain. Arch Neurol 2007; 64:1706-1711.
38. Goodman AB. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci USA 1998; 95:7240-7244.
39. Wan C, Shi Y, Zhao X, Tang W, Zhang M, Ji B et al. Positive association between ALDH1A2 and schizophrenia in the Chinese population. Prog Neuro- Psychopharmacol Biol Psychiatry 2009; 33:1491–1495.
40. Corti A, Casini AF, Pompella A. Cellular pathways for transport and efflux of ascorbate and dehydroascorbate. Arch Biochem Biophys 2010; 500:107-115.
41. Belin S, Kaya F, Burtey S, Fontes M. Ascorbic acid and gene expression: another example of regulation of gene expression by small molecules. Curr Genomics 2010; 11:52-57.
42. Diliberto EJ Jr, Menniti FS, Knoth J, Daniels AJ, Kizer JS, Viveros OH. Adrenomedullary chromaffin cells as a model to study the neurobiology of ascorbic acid:from monooxygenation to neuromodulation. Ann N Y Acad Sci 1987; 498:28- 53.
43. Rice ME. Ascorbate regulation and its neuroprotective role in the brain. Trends Neurosci 2000; 23:209-216.
44. Agus DB, Gambhir SS, Pardridge WM, Spielholz C, Baselga J, Vera JC, Golde DW. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest 1997; 100:2842-2848.
45. Verrax J, Calderon B. The controversial place of vitamin C in cancer treatment. Biochem Pharmacol 2008; 76:1644-1652.
46. Eck P, Erichsen HC, Taylor JG, Yeager M, Hughes AL, Levine M et al. Comparison of the genomic structure and variation in the two human sodium-dependent vitamin C transporters, SLC23A1 and SLC23A2. Hum Genet 2004; 115:285-294.
47. Meredith ME, Harrison FE, May JM. Differential regulation of the ascorbic acid transporter SVCT2 during development and in response to ascorbic acid depletion. Biochem Biophys Res Commun 2011; 414:737-742.
48. Spector R. Nutrient transport systems in brain: 40 years of progress. J Neurochem 2009; 111:315-320.
49. Bánhegyi G, Braun L, Csala M, Puskás F, Mandi J. Ascorbate metabolism and its regulation in animals. Free Radic Biol Med 1997; 23:793-803.
50. Spector R, Johanson C. Micronutrient and urate transport in choroid plexus and kidney:Implications for drug therapy. Pharm Res 2006; 23:2515-2524.
51. Mun GH, Kim MJ, Lee JH, Kim HJ, Chung YH, Chung YB et al. Immunohistochemical study of the distribution of sodium-dependent vitamin C transporters in adult rat brain. J Neurosci Res 2006; 83:919-928.
52. Qiu S, Li L, Weeber EJ, May JM. Ascorbate transport by primary cultured neurons and its role in neuronal function and protection against excitotoxicity. J Neurosci Res 2007; 85:1046-1056.
53. Kaempf-Rotzoll DE, Traber MG, Aral H. Vitamin E and transfer proteins. Curr Opin Lipidol 2003; 14:249-254.
54. Takada T, Suzuki H. Molecular mechanisms of membrane transport of vitamin E. Mol Nutr Food Res 2010; 54:616-622.
55. Goti D, Hrzenjak A, Levak-Frank S, Frank S, van der Westhuyzen DR, Malle E et al. Scavenger receptor class B, type I is expressed in porcine brain capillary endothelial cells and contributes to selective uptake of HDL-associated vitamin E. J Neurochem 2001; 76:498-508.
56. Copp RP, Wisniewski T, Hentati F, Larnaout A, Ben Hamida M, Kayden HJ. Localization of α-tocopherol transfer protein in the brains of patients with ataxia with vitamin E deficiency and other oxidative stress related neurodegenerative disorders. Brain Res 1999; 822:80-87.
57. Albers JJ, Vuletic S, Cheung MC. Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism. Biochim Biophys Acta 2011; 1821:345-357.
58. Traber MG. Vitamin E regulatory mechanisms. Annu Rev Nutr 2007; 27:347-362.
59. Borel P, Moussa M, Reboul E, Lyan B, Defoort C, Vincent-Baudry S et al. Human plasma levels of vitamin E and carotenoids are associated with genetic polymorphisms in genes involved in lipid metabolism. J Nutr 2007; 137:2653-2659.
60. Boscoboinik D, Szewczyk A, Hensey C, Azzi A. Inhibition of cell proliferation by alpha-tocopherol. Role of protein kinase C. J Biol Chem 1991; 266:6188-6194.
61. Ricciarelli R, Tasinato A, Clément S, Ozer NK, Boscoboinik D, Azzi A. alpha- Tocopherol specifically inactivates cellular protein kinase C alpha by changing its phosphotylation state. Biochem J 1998; 334:243-249.
62. Zingg JM, Libinaki R, Lai CQ, Meydani M, Gianello R, Ogru E et al. Modulation of gene expression by α-tocopherol and α-tocopherol phosphate in THP-1 monocytes. Free Radic Biol Med 2010; 49:1989-2000.
63. Zingg JM. Modulation of signal transduction by vitamin E. Mol Aspects Med 2007; 28:481-506.
64. Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism:increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin-the antioxidant proteins. Life Sci 2004; 75:2539-2549.
65. Al-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L. Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children. Clin Biochem 2009; 42:1032-1040.
66. Yorbık Ö, Sayal A, Akay C, Söhmen T. Otistik bozukluğu olan çocuklarda antioksi- dan enzimlerin ve bunlarla ilgili eser elementlerin araştırılması. Çocuk ve Gençlik Ruh Sağlığı Dergisi 2000; 7:173-181.
67. Bakkaloğlu B. Otistik bozuklukta antioksidan enzim ve antioksidan vitamin düzeyle- ri, malondialdehit ve glutatyon düzeyleri (Uzmanlık tezi). Ankara, Hacettepe Üniver- sitesi, 2007.
68. Uyanık O, Doğangün B, Kayaalp L, Korkmaz B, Dervent A. Food faddism causing vision loss in autistic child. Childcare Health Dev 2006; 32:601-602.
69. Duggan CP, Westra SJ, Rosenberg AE. Case records of the Massachusetts General Hospital. Case 23-2007: a 9-year-old-boy with bone pain, rash, and gingival hypertrophy. N Engl J Med 2007; 357:392-400.
70. Kimmoun A, Leheup B, Feillet F, Dubois F, Morali A. Hypercalcemia revealing iatrogenic hypervitaminosis A in a child with autistic troubles. Arch Pediatr 2008; 15:29-32.
71. Adams J, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med 2004; 10:1033-1039.
72. Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17:765-774.
73. Bošković M, Vovk T, Kores Plesničar B, Grabnar I. Oxidative stress in schizophrenia. Curr Neuropharmacol 2011; 9:301-312.
74. Li XF, Zheng YL, Xiu MH, Chen da C, Kosten TR, Zhang XY. Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35:1064-1067.
75. Raffa M, Atig F, Mhalla A, Kerkeni A, Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry 2011; 11:124.
76. Derin D, Yazıcı A, Erkoç Ş. Şizofrenik bozukluğu olan hastalarda serbest radikal metabolizması ve nonenzimatik antioksidan savunma sistemi elemanlarının incelen- mesi. Klinik Psikofarmakoloji Bülteni 2001; 11:174-182.
77. Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J et al. Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsychiatry Clin Neurosci 2005; 17:227-231.
78. Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 2005; 182:494-498.
79. Sivrioglu EY, Kirli S, Sipahioglu D, Gursoy B, Sarandöl E. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1493-1499.
80. Dadheech G, Mishra S, Gautam S, Sharma P. Oxidative stress, α-tocopherol, ascorbic acid and reduced glutathione status in schizophrenics. Indian J Clin Biochem 2006; 21:34-38.
81. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M et al. Pathways underlying neuroprogression in bipolar disorder:Focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35:804-817.
82. Can M, Güven B, Atik L, Konuk N. Lipid peroxidation and serum antioxidant enzymes activity in patients with bipolar and major depressive disorders. Journal of Mood Disorders 2011; 1:14-18.
83. Michael N, Sourgens H, Arolt V, Erfurth A. Severe tardive dyskinesia in affective disorders: treatment with vitamin E and C. Neuropsychobiol 2002; 46(suppl 1):28- 30.
84. Ceylan M, Sener S, Bayraktar AC, Kavutcu M. Oxidative imbalance in child and adolescent patients with attention-deficit/hyperactivity Neuropsychopharmacol Biol Psychiatry 2010; 34:1491-1494. disorder. Prog
85. Joshi K, Lad S, Kale M, Patwardhan B, Mahadik SP, Patni B et al. Supplementation with flax oil and vitamin C improves the outcome of Attention Deficit Hyperactivity Disorder (ADHD). Prostaglandins Leukot Essent Fatty Acids 2006; 74:17-21.
86. Gelain DP, Bittencourt Pasquali MA, Caregnato FF, Moreira JC. Vitamin A (retinol) up-regulates the receptor for advanced glycation endproducts (RAGE) through p38 and Akt oxidant-dependent activation. Toxicology 2011; 289:38-44.
87. Derviş E. Oral antioksidanlar. Dermatoz 2011; 2:263-267.
88. Buettner GR, Jurkiewicz BA. Cataliytic metals, ascorbate and free radicals: combinations to avoid. Radiat Res 1996; 145:532-541.
89. Betül Mazlum, Uzm. Dr., İstanbul Üniversitesi, Deneysel Tıp Araştıma Enstitüsü, Sinirbilim Anabilim Dalı, İstanbul.